Weaver Consulting Group Has $900,000 Stock Position in Johnson & Johnson (NYSE:JNJ)

Weaver Consulting Group lowered its holdings in Johnson & Johnson (NYSE:JNJ – Get Rating) by 9.6% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,092 shares of the company’s stock after selling 539 shares during the period. Weaver Consulting Group’s holdings in Johnson & Johnson were worth $900,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of the business. Geller Advisors LLC lifted its holdings in shares of Johnson & Johnson by 7.5% during the 2nd quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock worth $1,644,000 after acquiring an additional 648 shares during the period. Lincoln Capital Corp lifted its holdings in shares of Johnson & Johnson by 15.9% during the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock worth $218,000 after acquiring an additional 183 shares during the period. Ieq Capital LLC lifted its holdings in shares of Johnson & Johnson by 5.1% during the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock worth $20,912,000 after acquiring an additional 6,154 shares during the period. Ranch Capital Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 3.2% during the 2nd quarter. Ranch Capital Advisors Inc. now owns 10,154 shares of the company’s stock worth $1,802,000 after acquiring an additional 318 shares during the period. Finally, RFG Advisory LLC lifted its holdings in shares of Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock worth $3,900,000 after acquiring an additional 594 shares during the period. Institutional investors own 67.94% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on JNJ. Piper Sandler cut their price target on shares of Johnson & Johnson from $55.00 to $52.00 in a report on Monday, February 6th. Citigroup upped their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a research report on Monday, December 12th. StockNews.com initiated coverage on shares of Johnson & Johnson in a research report on Thursday. They set a “strong-buy” rating for the company. Cantor Fitzgerald reiterated an “overweight” rating and set a $215.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 1st. Finally, Atlantic Securities upped their price objective on shares of Johnson & Johnson from $160.00 to $168.00 and gave the stock a “neutral” rating in a research report on Wednesday, January 25th. Seven equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $174.73.

Insider Buying and Selling

In related news, insider James D. Swanson sold 1,062 shares of the stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares of the company’s stock, valued at $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.35% of the stock is owned by insiders.

Johnson & Johnson Trading Down 1.1 %

JNJ opened at $152.38 on Friday. Johnson & Johnson has a twelve month low of $150.71 and a twelve month high of $186.69. The company has a quick ratio of 0.77, a current ratio of 0.99 and a debt-to-equity ratio of 0.35. The company has a fifty day moving average of $161.97 and a 200-day moving average of $167.88. The stock has a market cap of $396.84 billion, a PE ratio of 22.61, a price-to-earnings-growth ratio of 2.65 and a beta of 0.54.

Johnson & Johnson (NYSE:JNJ – Get Rating) last posted its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. Johnson & Johnson had a net margin of 18.90% and a return on equity of 35.76%. The company had revenue of $23.71 billion during the quarter, compared to analysts’ expectations of $23.90 billion. During the same period in the prior year, the company posted $2.13 earnings per share. Johnson & Johnson’s revenue for the quarter was down 4.4% compared to the same quarter last year. On average, sell-side analysts predict that Johnson & Johnson will post 10.5 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st were paid a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a yield of 2.97%. The ex-dividend date of this dividend was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is presently 67.06%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.